Idea/Target | Lead | In vivo PoC | IND Enabling Studies | Phase 1 | Phase 2 | Phase 3 | Launch | |
---|---|---|---|---|---|---|---|---|
LUCID-MS |
|
Anticipated 4th Quarter 2022 | ||||||
LUCID-PSYCH |
|
Anticipated 4th Quarter 2022 | ||||||
FSD-201 |
|
Anticipated 2nd Quarter 2022 |
Lucid-PSYCH | |
Development Stage | Preclinical |
Target Condition | Mental health and neurodegenerative conditions |
Proprietary molecules | Yes |
Time to Market | 5-8 years |
IP/Innovation | Yes |
Market Access Strategy | Multiple entry points |
Proposed mechanism of action of PEA with red lines indicating canonical signaling, black lines as strongly supported, and grey as hypothesized (the Basal Phermacology of Palmitoylethanolamide)
Receive most valuable updates straight into your inbox
SIGN UP TODAY
PLEASE SEND INVESTOR INQUIRIES TO [email protected]
ALL OTHER INQUIRIES PLEASE EMAIL [email protected]
JOIN OUR TEAM
Careers